These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 3625258)

  • 41. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
    Miederer M; McDevitt MR; Borchardt P; Bergman I; Kramer K; Cheung NK; Scheinberg DA
    Clin Cancer Res; 2004 Oct; 10(20):6985-92. PubMed ID: 15501978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reassessment of patient response to monoclonal antibody 3F8.
    Cheung NV; Lazarus H; Miraldi FD; Berger NA; Abramowsky CR; Saarinen UM; Spitzer T; Strandjord SE; Coccia PF
    J Clin Oncol; 1992 Apr; 10(4):671-2. PubMed ID: 1548529
    [No Abstract]   [Full Text] [Related]  

  • 43. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a.
    Handgretinger R; Baader P; Dopfer R; Klingebiel T; Reuland P; Treuner J; Reisfeld RA; Niethammer D
    Cancer Immunol Immunother; 1992; 35(3):199-204. PubMed ID: 1638557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a.
    Mayer P; Handgretinger R; Bruchelt G; Schaber B; Rassner G; Fierlbeck G
    Melanoma Res; 1994 Apr; 4(2):101-6. PubMed ID: 8069095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
    Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
    J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
    Cheung NK; Cheung IY; Kushner BH; Ostrovnaya I; Chamberlain E; Kramer K; Modak S
    J Clin Oncol; 2012 Sep; 30(26):3264-70. PubMed ID: 22869886
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
    Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
    Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Mol Immunol; 1990 Oct; 27(10):957-64. PubMed ID: 2233757
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.
    Heiner JP; Miraldi F; Kallick S; Makley J; Neely J; Smith-Mensah WH; Cheung NK
    Cancer Res; 1987 Oct; 47(20):5377-81. PubMed ID: 3115567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
    Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell.
    Saito M; Yu RK; Cheung NK
    Biochem Biophys Res Commun; 1985 Feb; 127(1):1-7. PubMed ID: 2579648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.
    Houghton AN; Mintzer D; Cordon-Cardo C; Welt S; Fliegel B; Vadhan S; Carswell E; Melamed MR; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1242-6. PubMed ID: 3883355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
    J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2.
    Patel K; Rossell RJ; Pemberton LF; Cheung NK; Walsh FS; Moore SE; Sugimoto T; Kemshead JT
    Br J Cancer; 1989 Dec; 60(6):861-6. PubMed ID: 2481486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
    Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
    Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
    Mujoo K; Cheresh DA; Yang HM; Reisfeld RA
    Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.